Juncture Wealth Strategies Trimmed Supernus Pharmaceuticals (SUPN) Holding; Dragoneer Investment Group Upped Makemytrip Limited Mauritius (MMYT) Position By $2.39 Million

March 19, 2018 - By Linda Rogers

Juncture Wealth Strategies Llc decreased Supernus Pharmaceuticals Inc (SUPN) stake by 29.79% reported in 2017Q3 SEC filing. Juncture Wealth Strategies Llc sold 11,015 shares as Supernus Pharmaceuticals Inc (SUPN)’s stock rose 29.12%. The Juncture Wealth Strategies Llc holds 25,958 shares with $1.04 million value, down from 36,973 last quarter. Supernus Pharmaceuticals Inc now has $2.26B valuation. The stock decreased 1.85% or $0.825 during the last trading session, reaching $43.875. About 69,639 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since March 19, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

Dragoneer Investment Group Llc increased Makemytrip Limited Mauritius (MMYT) stake by 18.07% reported in 2017Q3 SEC filing. Dragoneer Investment Group Llc acquired 85,368 shares as Makemytrip Limited Mauritius (MMYT)’s stock rose 2.51%. The Dragoneer Investment Group Llc holds 557,868 shares with $16.04 million value, up from 472,500 last quarter. Makemytrip Limited Mauritius now has $3.52 billion valuation. The stock decreased 0.29% or $0.1 during the last trading session, reaching $34.85. About 12,463 shares traded. MakeMyTrip Limited (NASDAQ:MMYT) has risen 111.67% since March 19, 2017 and is uptrending. It has outperformed by 94.97% the S&P500.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on May, 8. They expect $0.34 EPS, up 78.95% or $0.15 from last year’s $0.19 per share. SUPN’s profit will be $17.52 million for 32.26 P/E if the $0.34 EPS becomes a reality. After $0.44 actual EPS reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.73% negative EPS growth.

Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.12, from 0.98 in 2017Q2. It is positive, as 22 investors sold SUPN shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Piermont Cap Mgmt Incorporated holds 0.14% or 10,290 shares. United Capital Advisers Ltd Limited Liability Company holds 47,052 shares. Nicholas Invest Partners Limited Partnership has 0.2% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 73,869 shares. 754,304 are owned by Ashford Capital Mngmt. Teachers Retirement System Of The State Of Kentucky invested in 0.01% or 17,000 shares. The New York-based Qs Invsts Llc has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). First Republic Investment Mngmt accumulated 10,933 shares or 0% of the stock. Hutchin Hill Cap LP accumulated 34,204 shares. Smith Asset Management Group Lp invested in 61,367 shares. 12,840 are held by Mason Street Lc. Rhumbline Advisers stated it has 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Moreover, Cim Ltd Liability Corporation has 0.2% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Keybank National Association Oh reported 22,880 shares or 0.01% of all its holdings. Bancshares Of Montreal Can holds 0% or 38,785 shares. Perigon Wealth Management Ltd Liability Corp holds 0.02% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 1,674 shares.

Since January 2, 2018, it had 0 insider buys, and 7 sales for $8.26 million activity. Vaughn Victor also sold $258,928 worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares. 20,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares with value of $899,500 were sold by Bhatt Padmanabh P.. Shares for $2.18 million were sold by PATRICK GREGORY S.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 38 analyst reports since August 26, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Buy” rating and $50.0 target in Monday, October 23 report. Cantor Fitzgerald maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Wednesday, February 28. Cantor Fitzgerald has “Buy” rating and $52.0 target. The stock has “Buy” rating by Janney Capital on Monday, December 4. The firm earned “Market Perform” rating on Monday, July 18 by Northland Capital. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, July 5 report. FBR Capital maintained the stock with “Buy” rating in Monday, November 20 report. The rating was downgraded by Stifel Nicolaus to “Hold” on Tuesday, September 19. On Wednesday, November 8 the stock rating was maintained by B. Riley & Co with “Buy”. The rating was maintained by Cowen & Co on Tuesday, September 19 with “Buy”. On Wednesday, February 28 the stock rating was maintained by Piper Jaffray with “Hold”.

Among 5 analysts covering MakeMyTrip (NASDAQ:MMYT), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. MakeMyTrip had 13 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Friday, October 13 with “Hold”. The rating was downgraded by Nomura to “Reduce” on Tuesday, February 23. Jefferies maintained MakeMyTrip Limited (NASDAQ:MMYT) on Friday, February 9 with “Hold” rating. As per Thursday, August 10, the company rating was downgraded by Jefferies. The firm has “Neutral” rating by Nomura given on Friday, June 3. The firm has “Buy” rating by J.P. Morgan given on Tuesday, February 27. The firm has “Hold” rating given on Friday, October 30 by Deutsche Bank. As per Thursday, November 2, the company rating was maintained by Jefferies.

Dragoneer Investment Group Llc decreased Appfolio Inc stake by 792,329 shares to 1.10 million valued at $52.81 million in 2017Q3. It also reduced 58 Com Inc (NYSE:WUBA) stake by 128,129 shares and now owns 1.13M shares. Jd Com Inc (NASDAQ:JD) was reduced too.